Please ensure Javascript is enabled for purposes of website accessibility

Should Novartis Investors Worry About This Supreme Court Ruling?

By Max Macaluso - Apr 3, 2013 at 6:30PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

How will this ruling on Glivec's patent affect Novartis' revenue this year?

On Monday, the fascinating conclusion to a lengthy court battle between Swiss drugmaker Novartis (NVS 0.89%) and the Supreme Court of India was revealed. The court ruled that Novartis' top-selling blockbuster drug Glivec (which is branded as Gleevec in the U.S.) should not be granted patent protection, which means that generic competitors can continue manufacturing their own versions of the drug in India. As the debate continues over the long-term implications of this controversial decision, investors are wondering how this ruling actually impacts Novartis' sales. In the following video, health care analyst Max Macaluso discusses the effect of this decision on Novartis' top line.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Novartis AG Stock Quote
Novartis AG
$88.46 (0.89%) $0.78

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/19/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.